Effects of CYP3A5 genetic polymorphisms on metabolism of tacrolimus in patients after kidney transplantation
10.13481/j.1671-587X.20180315
- Author:
Mingrui WANG
1
Author Information
1. Department of Urinary System Diseases Treatment Center, First Hospital, Jilin University
- Publication Type:Journal Article
- Keywords:
CYP3A5 genotype;
Genetic polymorphism;
Kidney transplantation;
Tacrolimus
- From:
Journal of Jilin University(Medicine Edition)
2018;44(3):537-542
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effects of different CYP3A5 genotypes on the concentrations of tacrolimus in blood of the patients after kidney transplantation, and to provide the valuable evidence for personalized administration in the patients after kidney transplantation. Methods: The clinical materials of 115 patients after kidney transplantation were analyzed retrospectively. The patients were divided into three groups according to the CYP3A5 genotypes: CYP3A5 ∗ 1/ ∗ 1 group (11 cases), CYP3A5 ∗ 1/ ∗ 3 group (46 cases) and CYP3A5 ∗ 3/ ∗ 3 group (58 cases). The concentration/dosage (C0/D) values of tacrolimus in blood of the patients in three groups at 7 d, 1 month, 3 months, 6 months, 1 year, and 2 years after operation were detected, respectively. Results: Thedifferences of body mass index (BMI), age composition ratios and gender composition ratios of the patients were not significant between three groups (P>0. 05). Compared with CYP3A5 ∗ 1/ ∗ 3 group, the C0/D values of tacrolimus in blood of the patients in CYP3A5 ∗ 1/ ∗ 1 group at 7 d, 3 months, 1 year and 2 years after operation were decreased (P=0. Oil, P<0.01, P=0.022, P=0.024); compared with CYP3A5 ∗ 3/∗ 3 group, the C0/D values of tacrolimus in blood of the patients in CYP3A5 ∗ 1/ ∗ 1 group and CYP3A5 ∗ 1/ ∗ 3 group at 7 d, 1 months, 3 months, 6 months, 1 year and 2 years after operation were decreased (P
